How should an intermediate-risk (ATA) thyroid nodule with a cystic, nondiagnostic (Bethesda I) fine‑needle aspiration be managed?

Repeat FNA with Ultrasound Guidance Targeting the Solid Component

For an intermediate-risk (ATA/EU-TIRADS 4) thyroid nodule that is cystic and returned Bethesda I cytology, you should perform a repeat ultrasound-guided FNA at 1-3 months, specifically targeting any solid tissue component, and if the nodule remains predominantly cystic with insufficient solid tissue or yields a second nondiagnostic result, proceed to diagnostic surgical excision given the 17.6% malignancy risk in cystic nodules and the inability to exclude malignancy. 1, 2, 3

Algorithmic Approach

Step 1: Verify Technical Adequacy of Initial FNA

• Cystic nodules have significantly higher rates of nondiagnostic cytology—your result is expected, not reassuring 4, 5
• The 2022 French consensus guidelines specify that cysts should be emptied slowly with an 18-21G needle, but the solid component must be sampled with a 23-27G needle under ultrasound guidance 1
• Critical pitfall: A nondiagnostic result from a cystic nodule does NOT indicate benign disease—malignancy rates in cystic thyroid nodules reach 17.6% 3

Step 2: Characterize the Solid Component

According to the EU-TIRADS framework for intermediate-risk nodules 2:

• Measure the solid tissue portion separately from the fluid component
• Document the EU-TIRADS score of the solid portion specifically
• If the solid component is >50% of the nodule, malignancy risk increases substantially 2
• If the solid component is <25%, the nodule may be technically difficult to sample adequately

Step 3: Repeat FNA Strategy (1-3 Month Interval)

Perform repeat ultrasound-guided FNA with these specifications 1:

• Use an experienced operator—operator experience is the strongest predictor of diagnostic adequacy 6
• Target the solid/wall component under real-time ultrasound visualization
• Avoid sampling through gel (interferes with cytology) 1
• Use 23-27G needle for tissue sampling
• Perform 2-5 passes with back-and-forth and radial movements 1

Expected outcomes from repeat FNA:

• 31.8% will remain nondiagnostic 4
• Cystic composition >50% increases odds of repeat nondiagnostic result by 3-fold (OR=2.845) 5
• Older patients have incrementally higher risk of repeat nondiagnostic results 4

Step 4: Management Based on Repeat FNA Result

If Repeat FNA is Diagnostic (Bethesda II-VI):

• Manage according to the Bethesda category obtained

If Repeat FNA Remains Nondiagnostic (Second Bethesda I):

• Proceed to diagnostic surgical excision (lobectomy) 3, 7
• Rationale: Even with two consecutive nondiagnostic results, malignancy rate is 3.2% 5, and you cannot reliably exclude malignancy in an intermediate-risk nodule
• The overall malignancy rate in operated cystic nodules with nondiagnostic cytology is 17.6% 3
• No clinical or ultrasound parameters reliably predict benignancy in cystic nodules 3

Step 5: Surgical Planning Considerations

• Initial surgery should be lobectomy (not total thyroidectomy) for intermediate-risk nodules without definitive malignancy 8
• Be aware that 20.8% of patients initially treated with lobectomy may require completion thyroidectomy if malignancy is found and RAI therapy is indicated 8
• Most malignancies in indeterminate/nondiagnostic nodules are low-risk differentiated thyroid cancers (95.7%) with excellent outcomes 9

Key Evidence Considerations

The 2022 French consensus guidelines 1, 2 provide the most current framework and emphasize that:

• EU-TIRADS 4 nodules warrant FNA when >15mm (6-17% malignancy risk)
• Mixed/cystic nodules require separate characterization of the solid component
• Repeat FNA is appropriate at 1-3 month intervals

Important caveat: The research consistently shows that nondiagnostic cytology in cystic nodules should NOT be interpreted as reassuring 3, 7. The historical teaching that "nondiagnostic = benign" is dangerous—one study found 37% malignancy rate in operated nodules with nondiagnostic FNA 7.

What NOT to Do

• Do not simply observe an intermediate-risk nodule with nondiagnostic cytology
• Do not assume cystic nodules are benign
• Do not perform more than 2 FNAs—diminishing returns and delays definitive diagnosis
• Do not sample only the cystic fluid—this guarantees nondiagnostic results